Sanofi Total Non-Cash Items 2010-2024 | SNY
Sanofi annual/quarterly total non-cash items history and growth rate from 2010 to 2024. Total non-cash items can be defined as the total of all non-cash charges adjusting Net Income on the Cash Flows Statement
- Sanofi total non-cash items for the quarter ending December 31, 2024 were $4.545B, a 2.57% increase year-over-year.
- Sanofi total non-cash items for the twelve months ending December 31, 2024 were $6.503B, a 4.05% increase year-over-year.
- Sanofi annual total non-cash items for 2024 were $4.545B, a 2.57% increase from 2023.
- Sanofi annual total non-cash items for 2023 were $4.431B, a 62.88% increase from 2022.
- Sanofi annual total non-cash items for 2022 were $2.72B, a 21.98% decline from 2021.
Sanofi Annual Total Non-Cash Items
(Millions of US $) |
| 2024 |
$4,545 |
| 2023 |
$4,431 |
| 2022 |
$2,720 |
| 2021 |
$3,487 |
| 2020 |
$-4,374 |
| 2019 |
$6,000 |
| 2018 |
$2,977 |
| 2017 |
$-1,360 |
| 2016 |
$2,546 |
| 2015 |
$3,273 |
| 2014 |
$3,115 |
| 2013 |
$4,120 |
| 2012 |
$4,548 |
| 2011 |
$7,734 |
| 2010 |
$6,811 |
| 2009 |
$6,988 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$128.587B |
$44.458B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
